4.10.25.5Vertical

Rheumatology Management Organizations

PE-backed platforms consolidating rheumatology practices.

Market snapshot

These figures describe Rheumatology (4.10.25), the segment that Rheumatology Management Organizations sits within. They are not figures for Rheumatology Management Organizations on its own.

FragmentationConsolidatingEstimate

Within Offices of Physicians (NAICS 621111); the Census Bureau does not split physician offices by specialty, so rheumatology is not separately sized.

Business model & economics

Revenue model

Office reimbursement plus in-office biologic infusion margin

Key economics

Recurring revenue
High

chronic autoimmune care and infusion

EBITDA margin
18–28% with infusion ancillaries
Capex intensity
Low

Characteristics

  • In-office biologic infusion drives ancillary economics.
  • Autoimmune prevalence and biologics growth.
  • Rheumatologist shortage and emerging MSO interest.

M&A deal context

Deal activityModerate

Who’s acquiring

  • Infusion-focused MSO platforms
  • PE-backed rheumatology consolidators
  • Multispecialty acquirers

What’s driving deals

  • Roll-up for infusion ancillary economics.
  • Autoimmune and biologics demand.
  • Rheumatologist shortage.

Find Rheumatology Management Organizations acquisition targets

Search Acquisera’s index for companies classified under Rheumatology Management Organizations (4.10.25.5) and build a targeted deal pipeline.

Search companies